Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD

Data ReadoutpositiveNeuLogiqPositive

AI Analysis

Summary

Cumulus Neuroscience published final results from the CNS-102 study in Scientific Reports demonstrating that its NeuLogiq platform is feasible and usable for at-home cognitive assessment in patients with ALS and FTD, with high user satisfaction ratings.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

CNS-102 study published in Scientific Reports demonstrating NeuLogiq platform feasibility and usability for at-home multimodal cognitive assessment; 82% of ALS participants rated platform easy to use, 75% rated experience positively

Importance:5/10

Sentiment:

0.70

neuroscienceALSFTDcognitive assessmentpublicationdigital healthplatform validation

Read the original article

Published by PR Newswire Pharma on August 18, 2026 3:44 PM

Read Original